Study Of Angiomax In Infants Under Six Months With Thrombosis
Status:
Completed
Trial end date:
2004-12-01
Target enrollment:
Participant gender:
Summary
The goals of this study are:
1. To assess the safety of bivalirudin in infants under six months with arterial or venous
thrombosis;
2. To determine the dose of bivalirudin required to achieve adequate anticoagulation as
measured by the activated clotting time (ACT) or activated partial thromboplastin time
(aPTT) in Infants Under Six Months with arterial or venous thrombosis;
3. To determine the outcome of patients on bivalirudin with respect to thrombus resolution
and bleeding complications compared to patients on unfractionated heparin (UH) or low
molecular weight heparin (LMWH).